feb 12, 2019: 9 a.m. - 10 a.m.
BIO%u2019s latest report on highly prevalent chronic diseases shows a slowdown in overall investment for new treatments for diabetes and obesity (available at http://www.bio.org/iareports). However, there remain signs of hope in the early-stage pipeline. This session will detail the drug pipeline, which research approaches are convincing skeptical investors, as well as opportunities for overcoming high-cost clinical trials and reimbursement barriers.
Moderator: Jason Butler, PhD, Managing Director and Senior Analyst, JMP Securities